NICE Endorse Boehringer’s Jardiance for Type 2 Diabetes

NICE Endorse Boehringer’s Jardiance for Type 2 DiabetesBoehringer Ingelheim and Eli Lilly Diabetes Alliance have announced that regulators for the National Health Service in England have deemed their drug, Jardiance (empagliflozin), as value for money.

The drug has been recommended by the National Institute for Health and Care Excellence (NICE) for treating some patients with type II diabetes.

The endorsement is a u-turn from October last year when the regulator announced that it was minded not to recommend Jardiance, and requested further information from Boehringer. Boehringer then submitted a new cost-effectiveness model which helped change NICE’s recommendation.

Although a range of treatments are already approved by NICE to manage diabetes, Boehringer noted that only 64.8% of people hit the NICE glycaemic target of 7.5%.

The director of the NICE Centre for Health Technology Evaluation, Carole Longson, also commented that while there are already several diabetes therapies available on the NHS “each has its advantages and disadvantages that affect how suitable they are for each individual,” so the addition of Jardiance will give patients “even more choice to ensure they get the treatment that is right for them.”

Source 1
Source 2

Industry News